Literature DB >> 3280594

Ovarian stimulation for in-vitro fertilization.

K Diedrich1, H van der Ven, S Al-Hasani, D Krebs.   

Abstract

In-vitro fertilization (IVF) and embryo transfer has become an accepted clinical method for the treatment of sterility. Different types of ovarian stimulation have been used successfully. The therapeutic principles behind the stimulation treatment in an IVF programme are the same as those applied in the treatment of normal and hypogonadotrophic ovarian insufficiency. These include clomiphene therapy with subsequent HCG administration, combined clomiphene/HMG administration and stimulation with HMG alone, followed by HCG. A new approach to the stimulation of follicular development and oocyte maturation is the use of pure FSH and GnRH analogues. The principal indications, results, advantages and disadvantages of these different schemes of ovarian stimulation for oocyte retrieval are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280594     DOI: 10.1093/oxfordjournals.humrep.a136649

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  4 in total

1.  Cumulus cell contribution to cytoplasmic maturation and oocyte developmental competence in vitro.

Authors:  H A Hassan
Journal:  J Assist Reprod Genet       Date:  2001-10       Impact factor: 3.412

Review 2.  Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomes.

Authors:  Israel Ortega; Juan A García-Velasco; Antonio Pellicer
Journal:  J Assist Reprod Genet       Date:  2018-07-28       Impact factor: 3.412

Review 3.  Drugs used in in vitro fertilisation procedures.

Authors:  I E Messinis
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

4.  Telomere length is short in PCOS and oral contraceptive does not affect the telomerase activity in granulosa cells of patients with PCOS.

Authors:  Ying Li; Bingbing Deng; Nengyong Ouyang; Ping Yuan; Lingyan Zheng; Wenjun Wang
Journal:  J Assist Reprod Genet       Date:  2017-05-06       Impact factor: 3.412

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.